NASH; Ian Alun

Patent Applications and Registrations

Patent applications and USPTO patent grants for NASH; Ian Alun.The latest application filed is for "pharmaceutical depot for n-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3-fluoro-4-(pyridin-2-y- lmethoxy)benzamide".

Company Profile

0.5.14

NASH; Ian Alun - Cheshire GB
Nash; Ian Alun - Macclesfield GB
Nash; Ian Alun - Mcclesfield GB

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pharmaceutical Depot For N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3-fluoro-4-(pyridin-2-y- Lmethoxy)benzamide App 20170135996 - BATEMAN; Nicola Frances ; et al.	2017-05-18
Pharmaceutical Depot For N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3-fluoro-4-(pyridin-2-y- Lmethoxy)benzamide App 20160030400 - BATEMAN; Nicola Frances ; et al.	2016-02-04
Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors Grant 8,742,124 - Brown , et al. June 3, 2	2014-06-03
Pharmaceutical Depot For 5-fluoro-2-[[(1s)-1-(5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-- Pyrazol-3-yl)amino]pyridine-3-carbonitrile App 20140045895 - JANIN; Armelle Marie-Laudine ; et al.	2014-02-13
Amide Derivatives Bearing A Cyclopropylaminoacarbonyl Substituent Useful As Cytokine Inhibitors App 20130035346 - BROWN; Dearg Sutherland ; et al.	2013-02-07
Pharmaceutical Depot For N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3-fluoro-4-(pyridin-2-y- Lmethoxy)benzamide App 20120149739 - Bateman; Nicola Frances ; et al.	2012-06-14
Pharmaceutical Depot For N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3-fluoro-4-(pyridin-2-y- Lmethoxy)benzamide App 20120149740 - BATEMAN; Nicola Frances ; et al.	2012-06-14
Pharmaceutical Depot For 5-fluoro-2-[[(1s)-1-(5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-- Pyrazol-3-yl)amino]pyridine-3-carbonitrile App 20120022110 - JANIN; Armelle Marie-Laudine ; et al.	2012-01-26
Amide Derivatives Bearing A Cyclopropylaminoacarbonyl Substituent Useful As Cytokine Inhibitors App 20120004243 - Brown; Dearg Sutherland ; et al.	2012-01-05
Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors Grant 7,943,776 - Brown , et al. May 17, 2	2011-05-17
Amide Derivatives App 20100256120 - Brown; Dearg Sutherland ; et al.	2010-10-07
Amide derivatives Grant 7,786,115 - Nash , et al. August 31, 2	2010-08-31
Amide derivatives Grant 7,750,154 - Brown , et al. July 6, 2	2010-07-06
4-oxoquinazolin-3-yl Benzamide Derivatives For The Treatment Of Cytokine Diseases App 20100152169 - Nash; Ian Alun ; et al.	2010-06-17
4-oxoquinazolin-3-yl benzamide derivatives for the treatment of cytokine diseases Grant 7,696,215 - Nash , et al. April 13, 2	2010-04-13
Compound 249 App 20090281150 - Bateman; Nicola Frances ; et al.	2009-11-12
4-oxoquinazolin-3-yl Benzamide Derivatives For The Treatment Of Cytokine Diseases App 20090124604 - Nash; Ian Alun ; et al.	2009-05-14
Amide Derivatives App 20080146566 - Nash; Ian Alun ; et al.	2008-06-19
Amide derivatives App 20070043065 - Brown; Dearg Sutherland ; et al.	2007-02-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.